Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension

Published:2020-10 Issue:4 Volume:10 Page:1-11
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Sitbon Olivier¹,Nikkho Sylvia²,Benza Raymond³,Deng Chunqin (CQ)⁴,Farber Harrison W.⁵,Gomberg‐Maitland Mardi⁶,Hassoun Paul⁷,Meier Christian²,Pepke‐Zaba Joanna⁸,Prasad Krishna⁹,Seeger Werner¹⁰,Corris Paul A¹¹

Affiliation:

1. Assistance Publique–Hôpitaux de ParisService de PneumologieHôpital BicêtreUniversité Paris‐SudLaboratoire d’Excellence en Recherche sur le Médicament et Innovation ThérapeutiqueLe Kremlin‐BicêtreFrance

2. Bayer AGClinical DevelopmentBerlinGermany

3. The Ohio State UniversityColumbusOHUSA

4. United Therapeutics CorporationRaleigh‐DurhamNCUSA

5. Tufts Medical CenterBostonMAUSA

6. George Washington University of Medicine and Health SciencesWashington, DCUSA

7. Johns Hopkins University School of MedicineBaltimoreMDUSA

8. Royal Papworth Hospital NHS Foundation TrustCambridgeUK

9. Medicines and Healthcare Products Regulatory Agency (MHRA)LondonUK

10. University of Giessen and Marburg Lung Center (UGMLC)GiessenGermany

11. Clinical and Translational Research Institute Newcastle UniversityNewcastle upon TyneUK

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2045894020962960

Reference57 articles.

1. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension;Galie N;Rev Esp Cardiol (Engl Ed),2016

2. Survival in patients with idiopathic, familial, and anorexigen‐associated pulmonary arterial hypertension in the modern management era;Humbert M;Circulation,2010

3. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long‐Term Pulmonary Arterial Hypertension Disease Management (REVEAL);Benza RL;Circulation,2010

4. An evaluation of long‐term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry;Benza RL;Chest,2012

5. Initiative FPFDD. The voice of the patient: pulmonary arterial hypertension. 2014. FDA’s Patient‐Focused Drug Development Initiative. Public Meeting: May 13 2014. Report Date: December 2014.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension;Pulmonary Circulation;2023-07

2. Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials;Frontiers in Cardiovascular Medicine;2023-06-12

3. The role of riociguat in combination therapies for pulmonary arterial hypertension;Respiratory Medicine;2023-05

4. The evolving landscape of pulmonary arterial hypertension clinical trials;The Lancet;2022-11

5. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension;Pulmonary Circulation;2022-10